News & Analysis
AI-powered market intelligence from WelthWest Research Desk. Original analysis, not just news.
389 articles · Page 33 of 33
Semaglutide Price War: Indian Pharma Giants Take On Global Obesity Giants
India’s pharmaceutical powerhouses have officially launched generic versions of the weight-loss blockbuster Semaglutide. This move democratizes access to GLP-1 therapy, challenging the pricing dominance of global giants like Novo Nordisk. We analyze the winners, losers, and what this means for your portfolio.
HDFC Bank Leadership Shakeup: Why Investors Are Hitting the Panic Button
The surprise departure of HDFC Bank's Non-Executive Chairman has sent shockwaves through the Indian financial sector. As the market's primary bellwether faces leadership volatility, investors are bracing for potential FII outflows. Here is the breakdown of why this governance shift matters for your Nifty 50 holdings.
Adani vs. Vedanta: The High-Stakes Battle for Jaiprakash Assets Heats Up
Vedanta has launched a formal challenge against the Adani Group’s NCLT-approved acquisition of Jaiprakash Associates. This move sparks a high-stakes legal battle that could delay asset integration for Adani and prolong the bankruptcy process for Jaiprakash, creating significant uncertainty in the distressed asset market.
Tata Capital Tax Shock: What the Rs 413 Crore Demand Means for NBFC Stocks
Tata Capital has been hit with a significant tax reassessment notice for FY18, casting a spotlight on the increasingly rigorous oversight of India's non-banking financial companies. Though the company remains confident, the development has sparked concerns about potential liquidity hits and regulatory scrutiny across the sector. We break down what this means for your portfolio.
Amir Chand Jagdish Kumar IPO: Is This Basmati Play Worth Your Portfolio?
Amir Chand Jagdish Kumar (ACJK) has officially set its IPO price at ₹212, bringing the basmati rice industry back into the primary market spotlight. This move offers a fresh look at the staples sector, but savvy investors must question if the valuation holds up against market leaders. We break down the impact on your portfolio and the competitive landscape.